ESR1 and breast carcinoma: To evaluate whether resistance of ER+ breast cancer cells to endocrine therapies could be linked, at least in part, to activation of FASN, we took advantage of an MCF-7 cell line engineered to overexpress HER2 (MCF-7/HER2-18 cells).